CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) announced new real-world data that show treatment with its leading multiple sclerosis (MS) therapies, TECFIDERA® (dimethyl fumarate) and TYSABRI® (natalizumab), early in the course of the disease may improve outcomes for people living with relapsing MS. These data were presented at the 69th annual meeting …
Tag Archives: Tecfidera
April, 2017
October, 2016
-
26 October
Diving Deeper with Oral MS Medications
Over the past few years, new oral medications for multiple sclerosis have gained Food and Drug Administration (FDA) approval, giving patients treatment options beyond injectable forms of medication. With multiple sclerosis (MS) medications, one of the primary goals is to extend the time between relapses, which is why these medications …
October, 2015
-
7 October
Biogen’s Tecfidera Demonstrates Long-Term Efficacy in Newly-Diagnosed MS Patients
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) will present new data that reinforce the proven efficacy and well-established safety profile of TECFIDERA® (dimethyl fumarate) in a broad range of people with relapsing-remitting multiple sclerosis (RRMS) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain …